More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...
From the first lawsuit to Lilly’s ultimatum: 18 months that reshaped the 340B program. For more than a year, major drugmakers have been pushing to replace the 340B program’s longstanding upfront ...
The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results